Invega

RSS

paliperidone

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Invega. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Invega.

For practical information about using Invega, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 17/10/2018

Authorisation details

Product details
Name
Invega
Agency product number
EMEA/H/C/000746
Active substance
paliperidone
International non-proprietary name (INN) or common name
paliperidone
Therapeutic area (MeSH)
  • Schizophrenia
  • Psychotic Disorders
Anatomical therapeutic chemical (ATC) code
N05AX13
Publication details
Marketing-authorisation holder
Janssen-Cilag International NV
Revision
16
Date of issue of marketing authorisation valid throughout the European Union
24/06/2007
Contact address
Turnhoutseweg, 30
B-2340 Beerse
Belgium

Product information

12/09/2018 Invega - EMEA/H/C/000746 - WS/1417/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Psycholeptics

Therapeutic indication

Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older.

Invega is indicated for the treatment of schizoaffective disorder in adults.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating